785 / 1631
JULIET: Patient characteristics
Baseline characteristics (N=99)
Median time from infusion to DCO, months
5.6
Median age, years
≥65 years, %
56 (range, 22−76)
23
ECOG PS 0/1, %
55/45
Stage III or IV disease, %
77
Double/triplet hits in
CMYC
/
BCL2
/
BCL6
genes,
%
15
Lymphodepleting chemo prior to infusion, %*
93
Median prior lines antineoplastic therapy, n
(range)
3 (1−6)
(95% ≥2; 51% ≥3 prior lines
therapy)
Bridging therapy, %
90
Prior auto-SCT, %
47
Median dose
3.1 × 10 (range, 0.1−6.0 × 10)
CTL019 transduced cells
*Prior to infusion, patients underwent restaging, 93% received lymphodepleting chemotherapy (73% received fludarabine 25 mg/m
2
/cyclophosphamide 250 mg/m
2
/day
×
3 days and 19% received bendamustine 90 mg/m
2
/day
×
2 days).